Source-Omega LLC's algae omega-3 oils are unapproved new drugs and misbranded because website claims say they treat or prevent disease.
What happened
FDA reviewed www.source-omega.com in May 2023 and found the site took orders for Source Oil Rosemary, Organic Lemon, and Organic Orange Algae Omega-3. FDA cited website statements that the products could help prevent Alzheimer's, lower triglycerides, prevent cognitive deficiencies, and double anti-cancer benefits. FDA said the products are not generally recognized as safe and effective for those uses, making them unapproved new drugs, and that they lack adequate directions for use and are misbranded.
What FDA found
Website claims that the algae omega-3 oils prevent or treat Alzheimer's, cancer, high triglycerides, cognitive deficiencies, and diabetes make the products drugs.
section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]The products are unapproved new drugs because FDA does not recognize them as safe and effective for those claimed uses and they lack FDA approval.
sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. §§ 321(p), 331(d), 355(a)]The products are misbranded because they do not bear adequate directions for use for diseases that a layperson cannot self-diagnose or treat without a licensed practitioner.
section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5Shipping these misbranded drugs in interstate commerce violates the Act.
section 301(a) of the Act [21 U.S.C. § 331(a)]
What FDA wants
FDA asks the company to notify it in writing within 15 working days of receipt, describing the specific steps taken to correct the violations, prevent recurrence, and include related documentation; if corrections cannot be completed in that time, the company must state why and when it will finish.
Who should pay attention
- dietary supplement brands selling algae omega-3 or DHA products
- online sellers and marketers who make disease claims for supplements
- companies that cite publications as support for product claims
This is a summary. Read the original letter on fda.gov.